ORTINGLOBE16.30

ORTIN GLOBAL LIMITED

· Pharma & Health
₹ CrorePeersLASAMANGALAMBIOFILCHEMVINEETLABKREBSBIOALPABALPHARMANATCAPSUQMcap ₹13.3 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity-284.75-42.80-59.85-59.85
Return on Assets-122.02-22.39-15.93-15.93
Return on Capital Employed-148.63-40.19-46.19-46.19
Return on Invested Capital-162.36-48.30-63.30-71.57
Margins
EBITDA Margin-309.60-258.21-1,030.05-1,618.67
Operating Margin-320.41-261.63-1,030.55-1,030.55
Incremental Operating Margin-331.7858.09
Pretax Margin-335.08-244.74-719.80-1,238.04
Net Income Margin-380.82-247.34-736.72-1,248.82
FCF Margin-173.88-120.95-556.82-556.82
Additional
Effective Tax Rate-13.65-1.06-2.35-0.87
Sustainable Growth Rate-284.75-42.80-59.85-59.85
Incremental Operating Margin %-331.7858.09480.14
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.